Cargando…
In Silico Design and Selection of New Tetrahydroisoquinoline-Based CD44 Antagonist Candidates
CD44 promotes metastasis, chemoresistance, and stemness in different types of cancer and is a target for the development of new anti-cancer therapies. All CD44 isoforms share a common N-terminal domain that binds to hyaluronic acid (HA). Herein, we used a computational approach to design new potenti...
Autores principales: | Ruiz-Moreno, Angel J., Reyes-Romero, Atilio, Dömling, Alexander, Velasco-Velázquez, Marco A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037692/ https://www.ncbi.nlm.nih.gov/pubmed/33810348 http://dx.doi.org/10.3390/molecules26071877 |
Ejemplares similares
-
Benchmark of Generic Shapes for Macrocycles
por: Reyes Romero, Atilio, et al.
Publicado: (2020) -
Correction to “Benchmark of Generic Shapes
for Macrocycles”
por: Reyes Romero, Atilio, et al.
Publicado: (2021) -
Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells
por: Aguirre-Alvarado, Charmina, et al.
Publicado: (2016) -
Steroidomimetic Tetrahydroisoquinolines
for the Design
of New Microtubule Disruptors
por: Leese, Mathew P., et al.
Publicado: (2011) -
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein
por: Reyes Romero, Atilio, et al.
Publicado: (2022)